Prolifagen Therapeutics

Prolifagen is a private, pre-clinical biotechnology company developing microRNA-based therapies to regenerate heart muscle after myocardial infarction and prevent progression to heart failure. Its lead program, PRO-302, combines miR-302 with an injectable hydrogel designed for local sustained release into damaged myocardium over roughly 7-10 days. The company’s approach is intended to transiently induce cardiomyocyte proliferation and restore functional cardiac tissue rather than only treating symptoms of post-infarct remodeling. Prolifagen appears to be a University of Pennsylvania spinout built around licensed intellectual property from academic founders including Ed Morrisey and Jason Burdick. The business remains focused on cardiovascular regeneration with an early pipeline centered on a single core therapeutic platform.